Breast cancer survivals and hormone therapy: estrogen and melatonin.
作者信息
Soares Júnior José Maria, Mota Bruna Salani, Nobrega Gabriela Bezerra, Filassi José Roberto, Sorpreso Isabel Cristina Espósito, Baracat Edmund Chada
机构信息
Laboratório de Ginecologia Estrutural e Molecular (LIM-58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo - São Paulo (SP), Brazil.
出版信息
Rev Assoc Med Bras (1992). 2023 Sep 25;69(10):e6910EDI. doi: 10.1590/1806-9282.6910EDI. eCollection 2023.
Abstract
摘要
相似文献
1
Breast cancer survivals and hormone therapy: estrogen and melatonin.乳腺癌幸存者与激素疗法：雌激素和褪黑素
Rev Assoc Med Bras (1992). 2023 Sep 25;69(10):e6910EDI. doi: 10.1590/1806-9282.6910EDI. eCollection 2023.
2
Breast cancer therapy based on melatonin.基于褪黑素的乳腺癌治疗
Recent Pat Endocr Metab Immune Drug Discov. 2012 May;6(2):108-16. doi: 10.2174/187221412800604581.
3
Melatonin: A Potential Therapeutic Option for Breast Cancer.褪黑素：乳腺癌的潜在治疗选择。
Trends Endocrinol Metab. 2020 Nov;31(11):859-871. doi: 10.1016/j.tem.2020.08.001. Epub 2020 Sep 3.
4
The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system.褪黑素对人乳腺癌细胞的生长抑制作用与雌激素反应系统有关。
Cancer Lett. 1992 Jul 10;64(3):249-56. doi: 10.1016/0304-3835(92)90050-6.
5
Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions.雌激素信号通路：乳腺癌与褪黑素抑癌作用之间的联系。
Cancer Detect Prev. 2006;30(2):118-28. doi: 10.1016/j.cdp.2006.03.002. Epub 2006 May 2.
6
Melatonin-estrogen interactions in breast cancer.褪黑素与雌激素在乳腺癌中的相互作用。
J Pineal Res. 2005 May;38(4):217-22. doi: 10.1111/j.1600-079X.2004.00207.x.
7
Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer.褪黑素对人乳腺癌中雌激素调节蛋白、生长因子和原癌基因的调节作用
J Pineal Res. 1995 Mar;18(2):93-103. doi: 10.1111/j.1600-079x.1995.tb00146.x.
8
5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells (MCF7).5-氟尿嘧啶减弱褪黑素对雌激素敏感的人乳腺癌细胞（MCF7）的抑癌作用。
Cancer Lett. 1994 Jun 15;81(1):95-8. doi: 10.1016/0304-3835(94)90170-8.
9
Melatonin as an Oncostatic Molecule Based on Its Anti-Aromatase Role in Breast Cancer.褪黑素作为一种基于其在乳腺癌中抗芳香化酶作用的抑瘤分子。
Int J Mol Sci. 2021 Jan 4;22(1):438. doi: 10.3390/ijms22010438.
10
Therapeutic potential of melatonin for breast cancer radiation therapy patients.褪黑素对乳腺癌放疗患者的治疗潜力。
Int J Radiat Biol. 2018 May;94(5):472-477. doi: 10.1080/09553002.2018.1446227. Epub 2018 Mar 14.
引用本文的文献
1
Analysis of Single Nucleotide Polymorphisms (SNPs) rs2234693 and rs9340799 of the Gene and the Risk of Breast Cancer.基因 rs2234693 和 rs9340799 单核苷酸多态性与乳腺癌风险的分析。
In Vivo. 2024 Sep-Oct;38(5):2134-2143. doi: 10.21873/invivo.13676.
2
Study of tumor budding and its association with clinicopathological parameters in breast carcinoma.研究肿瘤芽生及其与乳腺癌临床病理参数的关系。
Rev Assoc Med Bras (1992). 2024 Aug 16;70(7):e20240173. doi: 10.1590/1806-9282.20240173. eCollection 2024.
3
Are depression and poor sleep quality a major problem in Turkish Women receiving chemotherapy for breast cancer?抑郁症和睡眠质量差是接受乳腺癌化疗的土耳其女性面临的主要问题吗？
Rev Assoc Med Bras (1992). 2024 Apr 22;70(3):e20231377. doi: 10.1590/1806-9282.20231377. eCollection 2024.
本文引用的文献
1
Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts' perspective.打破开具和使用激素治疗更年期症状的障碍：专家观点。
Expert Rev Clin Pharmacol. 2023 Jan-Jun;16(6):507-517. doi: 10.1080/17512433.2023.2219056. Epub 2023 Jun 5.
2
A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause.更年期治疗的激素与非激素疗法选择综述
Int J Womens Health. 2023 May 25;15:825-836. doi: 10.2147/IJWH.S379808. eCollection 2023.
3
Hormonal and Metabolic Factors Influence the Action of Progesterone on the Endometrium of Women with Polycystic Ovary Syndrome.激素和代谢因素影响多囊卵巢综合征女性子宫内膜上孕酮的作用。
Diagnostics (Basel). 2023 Jan 19;13(3):382. doi: 10.3390/diagnostics13030382.
4
Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group.绝经激素治疗（MHT）的适应证：医学状况女性使用 MHT 的科学学会联盟的立场声明。MHT 适应证标准制定组。
Maturitas. 2022 Dec;166:65-85. doi: 10.1016/j.maturitas.2022.08.008. Epub 2022 Aug 30.
5
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.乳腺癌幸存者全身激素替代治疗的安全性：系统评价和荟萃分析。
Breast Cancer Res Treat. 2022 Jan;191(2):269-275. doi: 10.1007/s10549-021-06436-9. Epub 2021 Nov 3.
6
Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review.乳腺癌——流行病学、危险因素、分类、预后标志物及当前治疗策略——最新综述
Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287.
7
Pretreatment with melatonin improves ovarian tissue cryopreservation for transplantation.褪黑素预处理可改善卵巢组织的冷冻保存用于移植。
Reprod Biol Endocrinol. 2021 Feb 3;19(1):17. doi: 10.1186/s12958-021-00705-4.
8
Melatonin: A Potential Therapeutic Option for Breast Cancer.褪黑素：乳腺癌的潜在治疗选择。
Trends Endocrinol Metab. 2020 Nov;31(11):859-871. doi: 10.1016/j.tem.2020.08.001. Epub 2020 Sep 3.
9
Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process.褪黑素作为血管生成过程不同阶段化疗药物的辅助药物的作用。
Sci Rep. 2020 Mar 16;10(1):4790. doi: 10.1038/s41598-020-61622-x.
10
G protein-coupled estrogen receptor 1 (GPER1)/GPR30 increases ERK1/2 activity through PDZ motif-dependent and -independent mechanisms.G蛋白偶联雌激素受体1（GPER1）/GPR30通过依赖和不依赖PDZ基序的机制增加ERK1/2活性。
J Biol Chem. 2017 Jun 16;292(24):9932-9943. doi: 10.1074/jbc.M116.765875. Epub 2017 Apr 27.
Zotero 插件